| Factors |
Category |
p53 expression |
Pvalue |
| |
|
Negative (n=48) |
1+ (n=17) |
Overexpression (n=21) |
|
| Age (years) |
Mean±SD
(range) |
56.3±12.4
(33~80) |
59.6 ± 12.8 (44~80) |
54.5±12.3
(36~75) |
0.454 |
| Nuclear grade |
1,2 |
43 |
14 |
15 |
|
| |
3 |
4 |
3 |
6 (29%) |
0.100 |
| ER |
- |
9 |
4 |
15 (71%) |
|
| |
+ |
38 |
13 |
6 |
0.001 |
| PgR |
- |
12 |
10 |
15 (71%) |
|
| |
+ |
35 |
7 |
6 |
0.004 |
| HER2 |
- |
36 |
10 |
8 |
|
| |
+ |
12 |
7 |
13(62%) |
0.013 |
| Ki-67 |
- |
38 |
7 |
2 |
|
| |
+ |
10 |
10 |
19 (91%) |
<0.0001 |
| Surgery |
Bp |
35 |
11 |
10 (48%) |
|
| |
Bt |
12 |
6 |
10 (48%) |
0.263 |
| Adjuvant therapy |
None |
18 |
4 |
12 (57%) |
|
| Chemotherapy |
1 |
3 |
5 |
|
| |
Endocrine therapy |
26 |
9 |
4 |
|
| |
Chemo-endocrine therapy |
2 |
1 |
0 |
|
| Subtype |
Luminal A-like |
27 |
6 |
0 (0%) |
|
| Luminal B-like |
5 |
3 |
3(14%) |
|
| HER2 |
6 |
3 |
9 (43%) |
|
| Luminal/HER2 |
6 |
4 |
4 (11%) |
|
| Triple Negative |
7 |
2 |
3 (9%) |
|
|
